Biomea Fusion, Inc.
BMEAHealthcare|Biotechnology|US
$0.57
-0.02 (-3.51%)
DCF Value
$0.98
Tangible Book / Share
$0.17
Cash / Share
$0.48
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07502508 Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy | Type 2 Diabetes | P2 | Recruiting | 60 | RCT, Double-blind | icovamenib 100 mg, Placebo |
| NCT07502495 Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets | Type 2 Diabetes | P2 | Active | 64 | RCT, Double-blind | icovamenib 100mg, Placebo |
| NCT05731544 Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D) | Type 2 Diabetes Mellitus | P1P2 | Completed | 443 | RCT, Double-blind | BMF-219, Placebo |
| NCT06152042 Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus | P2 | Completed | 37 | RCT, Double-blind | BMF-219 |
| NCT07223216 Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants | Obesity | P1 | Completed | 90 | RCT, Double-blind | BMF-650 |
| NCT07254286 Food Effect Study in Healthy Volunteers | Healthy Volunteer | P1 | Completed | 60 | RCT, Open-label | Icovamenib, Icovamenib HPMC |
| NCT05918692 A Phase 1 Study of BMF-500 in Adults With Acute Leukemia | Acute Myeloid Leukemia | P1 | Completed | 35 | Open-label | BMF-500 |
| NCT05631574 Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | Non Small Cell Lung Cancer, Pancreatic Cancer | P1 | Terminated | 13 | Open-label | BMF-219 |
| NCT05153330 Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | P1 | Terminated | 55 | Open-label | BMF-219 |